Approach to the patient after relapse of hairy cell leukemia (Q37611080)

21 August 2017

1 reference

title

Approach to the patient after relapse of hairy cell leukemia (English)

1 reference

21 August 2017

1 reference

1 reference

Robert J Kreitman

1 reference

21 August 2017

David J P Fitzgerald

series ordinal

1 reference

21 August 2017

Ira Pastan

series ordinal

1 reference

21 August 2017

language of work or name

1 reference

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

50 Suppl 1

1 reference

21 August 2017

page(s)

32-37

1 reference

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Rituximab in relapsed or refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Immunotoxin therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Clinical experience with denileukin diftitox (ONTAK).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

The variant form of hairy-cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Immunophenotyping and differential diagnosis of hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Current treatment options in hairy cell leukemia and hairy cell leukemia variant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Pentostatin: impact on outcome in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Pentostatin induces durable remissions in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Splenectomy and treatments of historical interest

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Hairy cell leukemia variant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Hairy cell leukemia: towards a curative strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Eradication of minimal residual disease in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Rituximab as treatment for minimal residual disease in hairy cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903142216

Responses in refractory hairy cell leukemia to a recombinant immunotoxin

21 January 2018

1 reference

12 December 2020

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

1 reference

12 December 2020

Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab

1 reference

12 December 2020

ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products

1 reference

12 December 2020

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia

1 reference

12 December 2020

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias

1 reference

12 December 2020

Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine

1 reference

12 December 2020

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up study

1 reference

12 December 2020

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications

1 reference

12 December 2020

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

1 reference

12 December 2020

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

Long term outcome of patients with hairy cell leukemia treated with pentostatin

1 reference

12 December 2020

Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up

1 reference

12 December 2020

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

1 reference

12 December 2020

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

1 reference

12 December 2020

Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors

1 reference

12 December 2020

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

12 December 2020

Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin

1 reference

12 December 2020

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

1 reference

12 December 2020

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1 reference

12 December 2020

Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study

1 reference

12 December 2020

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

12 December 2020

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells

1 reference

12 December 2020

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

1 reference

12 December 2020

Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia

1 reference

12 December 2020

One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell

1 reference

12 December 2020

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia

1 reference

12 December 2020

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up

1 reference

12 December 2020

2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.

1 reference

12 December 2020

10.3109/10428190903142216

Identifiers

DOI

1 reference

21 August 2017

1 reference